Foresite Capital Fund IV, L.P. - Significant Ownership

Signature - Title
/s/ James Tananbaum - James Tananbaum, Managing Member of the General Partner
Location
San Francisco, CA
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Foresite Capital Fund IV, L.P..

Significant Ownership of Foresite Capital Fund IV, L.P.

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
LYEL Lyell Immunopharma, Inc. Common Stock, par value $0.0001 9.2% $12M $3.38M 27.2M +39.4% James B. Tananbaum Mar 31, 2025
MAZE Maze Therapeutics, Inc. Common Stock, par value $0.001 5.6% $19.2M 2.46M James Tananbaum Jan 31, 2025

Schedules 13D/G Reported by Foresite Capital Fund IV, L.P.:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Date Filed
* An asterisk sign (*) next to the price indicates that the price is likely invalid.